My Treatment Approach: My Treatment Approach: Navigating Genetic Testing and RET-Targeted Treatments in NSCLC

home / insights / my-treatment-approach-my-treatment-approach-navigating-genetic-testing-and-ret-targeted

Panelists discuss how genetic testing and RET-targeted therapies play a crucial role in guiding the treatment of advanced NSCLC, with a focus on optimizing first-line therapy and managing challenges in molecular testing and treatment sequencing.

Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

EP. 1: Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

Heather A. Wakelee, MD, FASCO;Jacob Sands, MD
December 10th 2024

Panelists discuss how the treatment approach for a 67-year-old man with stage IIIB+ non–small cell lung cancer (NSCLC) awaiting mutation testing involves balancing the urgency of initiating therapy with the importance of molecular testing to guide targeted treatment decisions.

Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy

EP. 2: Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy

Heather A. Wakelee, MD, FASCO;Jacob Sands, MD
December 10th 2024

Panelists discuss how molecular testing is crucial in guiding treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the prevalence of mutations like BRAF, KRAS, MET, RET, and EGFR, and their impact on selecting targeted therapies.